Elite Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit)
Elite Pharmaceuticals, Inc. (ELTP) reported Deferred Income Tax Expense (Benefit) of $1.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-13
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $1.32M, a 72.94% decline year-over-year.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $2.50M, a 7.69% increase year-over-year.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $1.48M, a 859.50% increase year-over-year.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $1.68M, a 29.08% increase year-over-year.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2026 was $10.54M, a 177.79% increase from fiscal 2025.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2025 was $3.80M.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$19.99M.
- Elite Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$2.17M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.32M 10-Q · filed 2026-08-13 | $3.82M derived: sum of 2 quarters · filed 2026-08-13 | $5.30M derived: sum of 3 quarters · filed 2026-08-13 | $6.98M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $3.98M derived: sum of 2 quarters · filed 2026-06-29 | $5.66M derived: sum of 3 quarters · filed 2026-06-29 | $10.54M 10-K · filed 2026-06-29 | |
| 2025-12-31 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $3.16M derived: sum of 2 quarters · filed 2026-02-17 | $8.04M 10-Q · filed 2026-02-17 | $10.36M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $6.56M 10-Q · filed 2025-11-14 | $8.89M derived: sum of 3 quarters · filed 2026-08-13 | $9.04M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $4.88M 10-Q · filed 2026-08-13 | $7.21M derived: sum of 2 quarters · filed 2026-08-13 | $7.36M derived: sum of 3 quarters · filed 2026-08-13 | $8.66M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $2.48M derived: sum of 2 quarters · filed 2026-06-29 | $3.78M derived: sum of 3 quarters · filed 2026-06-29 | $3.80M 10-K · filed 2026-06-29 | |
| 2024-12-31 | $154.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $1.45M derived: sum of 2 quarters · filed 2026-02-17 | $1.47M 10-Q · filed 2026-02-17 | -$455.78K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-09-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $1.32M 10-Q · filed 2025-11-14 | -$609.90K derived: sum of 3 quarters · filed 2025-11-14 | -$1.41M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $18.21K 10-Q · filed 2025-08-14 | -$1.91M derived: sum of 2 quarters · filed 2025-08-14 | -$2.71M derived: sum of 3 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | -$2.73M derived: sum of 2 quarters · filed 2025-06-30 | -$19.99M 10-K · filed 2025-06-30 | -$19.99M 10-K · filed 2024-07-01 | |
| 2023-12-31 | -$800.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | -$18.06M 10-Q · filed 2025-02-13 | |||
| 2023-09-30 | -$17.26M 10-Q · filed 2024-11-14 | ||||
| 2022-03-31 | -$2.17M 10-K · filed 2023-06-29 |